A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin (CLEE011 XUS02T)

Trial Profile

A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin (CLEE011 XUS02T)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Ribociclib (Primary)
  • Indications Gastrointestinal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 19 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Aug 2015 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top